A detailed history of Values First Advisors, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 19,692 shares of CLDX stock, worth $707,139. This represents 0.49% of its overall portfolio holdings.

Number of Shares
19,692
Previous 7,399 166.14%
Holding current value
$707,139
Previous $293,000 181.91%
% of portfolio
0.49%
Previous 0.18%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$35.22 - $51.88 $432,959 - $637,760
12,293 Added 166.14%
19,692 $826,000
Q4 2023

Jan 18, 2024

BUY
$22.61 - $40.65 $167,291 - $300,769
7,399 New
7,399 $293,000
Q2 2023

Aug 02, 2023

BUY
$30.29 - $38.28 $68,394 - $86,436
2,258 Added 42.59%
7,560 $256,000
Q1 2023

May 15, 2023

SELL
$34.78 - $47.43 $77,837 - $106,148
-2,238 Reduced 29.68%
5,302 $190,000
Q4 2022

Jan 20, 2023

BUY
$27.78 - $45.38 $209,461 - $342,165
7,540 New
7,540 $0

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.68B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.